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nonsusceptibilityAbstract Background: Data on susceptibility to ceftobiprole and colistin, and the complete
evolutionary trends of minimum inhibitory concentrations (MICs) of important carbapenem
agents among important pathogens collected in intensive care units (ICUs) in Taiwan are lack-
ing.
Methods: We surveyed the MIC distribution patterns of ceftobiprole and colistin and suscepti-
bility profiles of some important pathogens collected from patients hospitalized in intensive
care units (ICUs) of major teaching hospitals throughout Taiwan in 2007. We also investigated
the rates of nonsusceptibility to powerful carbapenems (imipenem, meropenem) among four
important species of Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Enterobac-
ter cloacae, and Proteus mirabilis) collected during the same period. MIC breakpoints recom-
mended by the Clinical and Laboratory Standards Institute in 2014 were applied.
Results: Colistin showed excellent in vitro activity (susceptibility rate, 96%) against Acineto-
bacter baumannii isolates but moderate (73e77% susceptibility rate) activity against isolates
of Pseudomonas aeruginosa and E. cloacae. The ceftobiprole MIC90 value was 4 mg/mL for
methicillin-resistant Staphylococcus aureus and 16 mg/mL for P. aeruginosa. The phenotype
of methicillin resistance did not markedly increase the MIC value of ceftobiprole among S.
aureus isolates. Interestingly, the proportion of isolates that displayed nonsusceptibility to imi-
penem was significantly higher among P. mirabilis isolates than among isolates of the other
three Enterobacteriaceae species, regardless of the production of extended-spectrum b-lacta-
mase.
Conclusion: Continuous monitoring of susceptibility profiles of ICU pathogens to important an-
tibiotics is warranted to provide appropriate antimicrobial regimens against infections in the
ICU.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The gradual increase in minimum inhibitory concentrations
(MICs) of glycopeptides for strains of Staphylococcus aureus
(i.e., glycopeptide creep) is a worrisome concern world-
wide.1 Infections caused by S. aureus strains with vanco-
mycin MIC levels 2 mg/L are almost always associated
with a reduction in clinical efficacy of vancomycin2,3 as well
as high morbidity and mortality rates.2,4 Multidrug-resistant
(MDR) gram-negative bacteria (GNB) are also an important
concern in intensive care units (ICUs) around the world.
Because of the coexistence of methicillin-resistant S.
aureus (MRSA) and MDR-GNB in most hospitals and nursing
homes, physicians often need to prescribe multiple antibi-
otics for the management of hospital-acquired and health
care-associated infections.5
Ceftobiprole, a novel cephalosporin that is effective
against MRSA6 and many derepressed AmpC b-lactamase-
producing enteric GNB species,7 but not against extended-
spectrum b-lactamase (ESBL)-producing Enter-
obacteriaceae spp.6 has been shown to be as effective as
cefepime against GNB, including Pseudomonas aeruginosaisolates.6 In addition, ceftobiprole exerted less potential of
selecting single-step P. aeruginosa mutants of AmpC hy-
perproducer than cefepime,8 ceftobiprole has high binding
affinity for penicillin-binding protein 2a (PBP2a) and PBP2x,
which renders it highly active against penicillin- and
ceftriaxone-resistant Streptococcus pneumoniae,6,9 MRSA
(regardless of the mecA expression level, and daptomycin
susceptibility), and vancomycin-nonsusceptible S. aureus
isolates.10 In Taiwan, there is a lack of in vitro suscepti-
bility data regarding ceftobiprole and colistin. The Sur-
veillance of Multicenter Antimicrobial Resistance in Taiwan
(SMART), launched in 2000, is designed to longitudinally
monitor the in vitro susceptibility profiles of clinical path-
ogens to important and future promising antibiotic agents,
particularly the pathogens isolated from ICUs over time
throughout Taiwan. Because the data regarding suscepti-
bility to colistin and ceftobiprole and serial profiles in
carbapenem nonsusceptibilities for the important clinical
isolates still lacked in our country, we conducted an in vitro
survey to evaluate the distributions of MIC values of cef-
tobiprole and colistin against S. aureus, important non-
fermentative GNB and Enterobacteriaceae isolates, and
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isolates of important ESBL-producing and non-ESBL-
producing Enterobacteriaceae species using the MIC
breakpoints recommended by the Clinical and Laboratory
Standards Institute (CLSI) in 2014.11
Methods
Bacterial isolates
From July 1, 2007 through December 31, 2007, a total of
1088 consecutive, nonduplicate isolates of Enter-
obacteriaceae, along with 200 isolates of S. aureus, 100
isolates of Acinetobacter baumannii, and 403 isolates of P.
aeruginosa (1 isolate per patient) were collected from pa-
tients in ICUs at 10 major teaching hospitals (5 in the
northern part, 1 in the central part, and 4 in the southern
part) throughout Taiwan. The Enterobacteriaceae isolates
comprised Escherichia coli (n Z 344), Klebsiella pneumo-
niae (n Z 359), Enterobacter cloacae (n Z 103), Cit-
robacter freundii (nZ 36), Serratia marcescens (nZ 102),
Morganella morganii (n Z 66), and Proteus mirabilis
(n Z 78), as reported in our previous study.12 Among the
sources of clinical specimens in this study, nearly one-
fourth (24.5%) of specimens were collected from sterile
sites (16.6% from bloodstream and 7.9% from other sterile
sites), whereas 43.1%, 9.4%, and 23% of all specimens were
collected from the respiratory tract, wounds, and other
nonsterile sites, respectively. In the current survey, the
number of clinical isolates submitted by each participating
hospital was nearly even. The MIC values of tested antibi-
otics against these clinical isolates collected in 2007 were
determined by the broth microdilution method in accor-
dance with CLSI guidelines. All isolates were stored at
70C in trypticase soy broth (Difco Laboratories, Detroit,
MI, USA) supplemented with 15% glycerol prior to testing.
Isolates were then transported to the National Taiwan
University Hospital, Taipei, Taiwan for further identifica-
tion by the Phoenix PMIC/ID-30 identification system (Bec-
ton Dickinson Systems, Sparks, MD, USA). E. coli ATCC 25922
and P. aeruginosa ATCC 27853 were used as quality control
strains for each run of MIC tests. MIC testing was repeated if
the results for ATCC strains were outside the expected
range recommended by the CLSI.
Detection of ESBL production, determination of
MICs, and nonsusceptibilities to carbapenem agents
For four species of Enterobacteriaceae (E. coli, K. pneu-
moniae, E. cloacae, and P. mirabilis) collected from ICU
settings in 2007, the modified double-disc synergy test,
which involves a disc containing cefepime 30 mg, with or
without clavulanic acid 10 mg (at a center-to-center dis-
tance of 30 mm), instead of a disc containing 4 mg clav-
ulanic acid,13 was applied to detect ESBL production if
isolates (E. coli, K. pneumoniae, E. cloacae, and P. mir-
abilis) had cefotaxime, ceftazidime, or cefepime MIC
values 2 mg/mL. The production of ESBL was considered
positive if the diameter of the cefepime disc increased
by  5 mm, or the zone diameter expanded by  50% of the
original size, as suggested by M’Zali et al.14 In addition, wedetermined the MIC values of carbapenem agents (imipe-
nem and meropenem, as well as ertapenem specifically for
P. mirabilis isolates, for the reasons described in the Dis-
cussion section) against these four species of Enter-
obacteriaceae isolates obtained as part of the SMART study
in 2007 as well as their susceptibility profiles according to
MIC breakpoints recommended by the CLSI in 2014.11
Investigations of MICs of colistin and ceftobiprole
against important ICU bacteria
We investigated the rates of susceptibility of Enter-
obacteriaceae members, P. aeruginosa, and A. baumannii
to colistin and surveyed the MIC values of ceftobiprole
against ICU isolates of S. aureus and P. aeruginosa. Oxacillin
MIC values were tested among all S. aureus isolates
collected in 2007. All of the antibiotic agents investigated
in this study were provided by their respective manufac-
turers. Ceftobiprole standard powder was provided by
Johnson and Johnson Pharmaceutical Research and Devel-
opment (Raritan, NJ, USA).
Statistical analyses
Categorical variables are presented as percentages and
were compared using the Chi-square test. Continuous var-
iables were compared using the Student t test or Man-
neWhitney U test, depending on the validity of normality
assumption. The coefficient of correlation between the MIC
levels of oxacillin and ceftobiprole among the S. aureus
isolates (overall vs. MRSA subgroup) was estimated by
appropriate correlation methods. All statistical calculations
were two-tailed and p < 0.05 was considered to represent
statistical significance. All statistical analyses were per-
formed using the statistical package SPSS for Windows
(version 17.0; SPSS Inc., Chicago, IL, USA).
Results
Susceptibility of Enterobacteriaceae species, P.
aeruginosa, and A. baumannii isolates to colistin
The in vitro data regarding susceptibilities to colistin among
isolates of the Enterobacteriaceae members, P. aeruginosa,
and A. baumannii obtained from patients hospitalized in
ICUs in 2007 are listed in Table 1. Some of the species
Enterobacteriaceae family evaluated in this ICU survey
exhibited relatively high rates of nonsusceptibility (>25%) to
this agent, with the exception of E. coli, K. pneumoniae,
and C. freundii. By contrast, the rates of susceptibility to
colistin were 76.7% for P. aeruginosa and 96% for A. bau-
mannii isolates collected in ICU settings in 2007.
Comparison of MIC levels of ceftobiprole against
isolates of P. aeruginosa and S. aureus
The MIC range, MIC50, and MIC90 values of ceftobiprole
against P. aeruginosa isolates obtained from patients in ICUs
in 2007 were 0.5e>128, 2 and 16 mg/mL, respectively.
Ceftobiprole inhibited 68% of P. aeruginosa isolates at a
Table 1 Susceptibility profile of isolates of Enterobacteriaceae species, Pseudomonas aeruginosa, and Acinetobacter bau-
mannii against colistin in intensive care units in Taiwan in 2007
Species (no.) MIC (mg/mL) Susceptibility
MIC range MIC50 MIC90 S (%) I (%) R (%)
Enterobacteriaceae spp. (n Z 1088)
Escherichia coli (n Z 344) 0.5e>128 1 1 334 (97.1) d 10 (2.9)
Klebsiella pneumoniae (n Z 359) 0.5e16 1 1 356 (99.2) d 3 (0.8)
Enterobacter cloacae (n Z 103) 0.5e>128 1 >128 75 (72.8) d 28 (27.2)
Citrobacter freundii (n Z 36) 1e16 1 8 30 (83.3) d 6 (16.7)
Serratia marcescens (n Z 102) 1e>128 >128 >128 9 (8.8) d 93 (91.2)
Morganella morganii (n Z 66) 1e>128 >128 >128 2 (3) d 64 (97)
Proteus mirabilis (n Z 78) 16e>128 >128 >128 0 (0) d 78 (100)
Nonfermentative gram-negative bacteria (n Z 503)
Pseudomonas aeruginosa (n Z 403) 2 - 8 2 4 309 (76.7) 61 (15.1) 33 (8.2)
Acinetobacter baumannii (n Z 100) 0.5e>32 1 2 96 (96) d 4 (4)
I Z intermediate; MIC Z minimum inhibitory concentration; R Z resistant; S Z susceptible.
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tration of 8 mg/mL, and 91.6% of P. aeruginosa isolates at a
concentration of 16 mg/mL (Table 2). We also found that the
MIC50 and MIC90 levels for methicillin-susceptible S. aureus
isolates (n Z 59) were 0.5 mg/mL and 0.5 mg/mL, respec-
tively, and that the MIC50 and MIC90 levels for MRSA isolates
(n Z 141) were 2 mg/mL and 4 mg/mL, respectively. About
88.7% (125/141) of the MRSA isolates had ceftobiprole MICs
of 2 mg/mL, and only one MRSA isolate had a ceftobiprole
MIC > 4 mg/mL (64 mg/mL; Table 2). The overall MICs of
oxacillin against S. aureus isolates correlated well with the
overall MICs of ceftobiprole (Spearman correlation coeffi-
cient, r Z 0.876, p < 0.001); however, there was a poor
correlation between the MICs of those two agents against
MRSA isolates (rZ 0.263, pZ 0.245). In addition, there was
a significantly higher proportion of the MRSA isolates with
oxacillin MICs >128 mg/mL among MRSA isolates with cef-
tobiprole MICs ranging from 2 mg/mL to 4 mg/mL than among
isolates with ceftobiprole MICs <2 mg/mL (p < 0.001).Carbapenem susceptibility among four species of
Enterobacteriaceae
Comparisons of susceptibilities of non-ESBL and ESBL-
producing isolates of four species of Enterobacteriaceae
to carbapenem agents (imipenem, meropenem) in 2007 are
shown in Table 3. It is worth noting that a few carbapenem-
nonsusceptible isolates were found in the ESBL and non-
ESBL subgroups of the four species. The absolute number
of carbapenem-nonsusceptible isolates in the respective
non-ESBL subgroups exceeded that in the ESBL subgroup ofTable 2 The percentages of isolates of Pseudomonas aeruginosa
different concentrations of ceftobiprole
Species, and % inhibited by the concentration(s) of ceftobiprole
Pseudomonas aeruginosa (n Z 403)
MRSA (n Z 141)
MRSA Z methicillin-resistant Staphylococcus aureus.the same species. However, there were no significant dif-
ferences in the number of carbapenem-nonsusceptible
isolates between the two subgroups of all four species. All
of the P. mirabilis isolates were susceptible to ertapenem
irrespective of ESBL production (MIC  0.06 mg/mL; data
not shown). Furthermore, a rightward shifting trend in
imipenem MIC values was noted for P. mirabilis (regardless
of ESBL production; Fig. 1A and B) and E. cloacae (ESBL
subgroup, Fig. 1A) isolates. This trend was not noted for
meropenem MIC levels (data not shown). Although the
proportion of imipenem-nonsusceptible P. mirabilis isolates
in the ESBL subgroup was significantly higher than that of
imipenem-nonsusceptible P. mirabilis isolates in the non-
ESBL-producing subgroup (50% vs. 32.8%, p Z 0.23), the
distribution of imipenem MIC values did not differ signifi-
cantly between the two P. mirabilis subsets (p Z 0.96). By
contrast, the distributions of imipenem MICs among P.
mirabilis isolates were significantly higher for both non-
ESBL- and ESBL-producing subgroups when compared to
the respective subgroups of the other three Enter-
obacteriaceae species (all p < 0.05). No such trend was
found in distribution of meropenem MICs among the four
species of the Enterobacteriaceae family.Discussion
This surveillance study of antimicrobial resistance among
important pathogens isolated from patients in the ICU re-
veals a number of important findings. First, colistin was
demonstrated to have excellent in vitro activity against A.
baumannii, which contrasted with moderate activityand methicillin-resistant Staphylococcus aureus inhibited by
1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL 16 mg/mL
15.9% 56.1% 68.0% 81.1% 91.6%
14.9% 88.7% 99.3% 99.3% 99.3%
Table 3 Minimum inhibitory concentration values of two carbapenem agents (imipenem, meropenem) against the species of
Enterobacteriaceae family (extended-spectrum b-lactamase vs. nonextended-spectrum b-lactamase producing isolates)
collected in 2007 and the rates of susceptibility evaluated by the minimum inhibitory concentration breakpoints of the Clinical
and Laboratory Standards Institute, 2014
Species and antibiotic evaluated MIC (mg/mL) Susceptibility
Range MIC50 MIC90 S (%) I (%) R (%)
Escherichia coli (ESBL) n Z 67
IMI 0.06e1 0.25 0.25 67 (100) 0 (0) 0 (0)
MEM 0.03e0.06 0.03 0.06 67 (100) 0 (0) 0 (0)
E. coli (non-ESBL), n Z 277
IMI 0.06e16 0.12 0.25 273 (98.6) 0 (0) 4 (1.4)
MEM 0.03e4 0.03 0.03 273 (98.6) 1 (0.4) 3 (1.1)
Klebsiella pneumoniae (ESBL) n Z 75
IMI 0.12e>128 0.25 0.5 70 (93.3) 1 (1.3) 4 (5.3)
MEM 0.03e>64 0.03 0.12 70 (93.3) 1 (1.3) 4 (5.3)
K. pneumoniae (non-ESBL), n Z 284
IMI 0.06e8 0.25 0.5 273 (96.1) 2 (0.7) 9 (3.2)
MEM 0.03e64 0.03 0.06 276 (97.2) 3 (1.1) 5 (1.8)
Enterobacter cloacae (ESBL), n Z 19
IMI 0.25e8 0.25 1 18 (94.7) 0 (0) 1 (5.3)
MEM 0.03e8 0.06 1 18 (94.7) 0 (0) 1 (5.3)
E. cloacae (non-ESBL), n Z 84
IMI 0.12e64 0.5 1 80 (95.2) 1 (1.2) 3 (3.6)
MEM 0.03e8 0.06 0.25 81 (96.4) 1 (1.2) 2 (2.4)
Proteus mirabilis (ESBL), n Z 14
IMI 0.25e4 1 4 7 (50) 3 (21.4) 4 (28.6)
MEM 0.03e0.25 0.12 0.25 14 (100) 0 (0) 0 (0)
P. mirabilis (non-ESBL), n Z 64
IMI 0.06e8 1 2 43 (67.2) 16 (25) 5 (7.8)
MEM 0.03e4 0.06 0.25 63 (98.4) 0 (0) 1 (1.6)
ESBL, extended-spectrum b-lactamase; IMI Z imipenem; MEM Z meropenem; MIC Z minimum inhibitory concentration.
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species of Enterobacteriaceae in 2007. Second, MICs of
ceftobiprole were very low for P. aeruginosa and MRSA
isolates, indicating that ceftobiprole is an attractive choice
for empirical management of infections in the ICU setting.
Third, we found that imipenem-nonsusceptible P. mirabilis
was present in ICUs of Taiwanese hospitals in 2007.
Although colistin was administered clinically for only a
short period of time in Taiwan prior to 2007, the rates of
nonsusceptibility among isolates of P. aeruginosa and A.
baumannii collected from ICUs in Taiwan in 2007 were
relatively higher (23.3% and 4%, respectively) than those
collected in Turkey during 2011e2012.15 Similarly, the rate
of susceptibility to colistin (76.7%) among P. aeruginosa
isolates obtained in 2007 from ICUs in Taiwan was signifi-
cantly lower than that among P. aeruginosa isolates ob-
tained from ICUs in the United States during 2009e2011
(99.4%).16 A search of the PubMed database revealed a
single small case series that documented the outcome of
patients with infections due to colistin-resistant enteric
GNB. In that study from Saudi Arabia, five of seven critically
ill patients with colistin-resistant Enterobacteriaceae spe-
cies (5 K. pneumoniae, 2 S. marcescens) were successfully
treated by various antimicrobial agents.17 More clinical
evidence is needed to evaluate the outcome of patients
with infection caused by colistin-resistant Enter-
obacteriaceae species.Studies have shown that ceftobiprole has a good phar-
macokinetic profile [a peak serum concentration of 35.5 mg/
mL and a high free-drug concentration (plasma protein-
bound degree, 16%)18] and a good pharmacodynamic profile
(the concentration above MIC is >50% of the total dosing
interval for MRSA isolates with vancomycin MICs < 4 mg/mL)
when the drug is administered at a dose of 500 mg every
8 hours with a 2-hour intravenous infusion.7 In this survey,
the ceftobiprole MIC90 value was 4 mg/mL against MRSA
isolates obtained from ICUs in Taiwan, which is twofold
higher than that reported in other surveys.6,10,19 It is note-
worthy that MRSA isolates with oxacillin MICs > 128 mg/mL
largely have ceftobiprole MIC values ranging from 2 mg/mL to
4 mg/mL. This suggests that elevatedmecA expression levels
in MRSA have little effect on the MICs of ceftobiprole, as
reported by Fritsche et al.20 In contrast to ceftaroline
fosamil, another anti-MRSA cephalosporin agent with mini-
mal in vitro activity against nonfermentative GNB (espe-
cially P. aeruginosa isolates),21 ceftobiprole was verified to
have a MIC90 value of 16 mg/mL against ICU isolates of P.
aeruginosa, a finding similar to that reported in other sur-
veys.19,22 Using Monte Carlo simulation, Lodise et al7 found
that a fair probability (62.0%) of target attainment for
maximal bactericidal performance (requiring at least 60% of
a total dosing interval for a ceftobiprole concentration being
above its MIC of the GNB organism) against P. aeruginosa
isolates could be achieved when 500 mg is administered
Figure 1. Cumulative minimum inhibitory concentration
(MIC) distribution curves for imipenem against (A) ESBL-
producing and (B) non-ESBL-producing Enterobacteriaceae
species (Escherichia coli, Klebsiella pneumoniae, Enterobacter
cloacae, and Proteus mirabilis) collected from intensive care
units in 2007 as part of the SMART study. ESBL Z extended-
spectrum b-lactamase.
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Therefore, ceftobiprole is a suitable monotherapy for
empirical management of many health care-acquired in-
fections in Taiwan.
Class A carbapenemase [especially, K. pneumoniae car-
bapenemase (KPC)] was not detected in the species of
Enterobacteriaceae collected in ICU settings in Taiwan
before 2011.23e25 Therefore, porin deficiency (imperme-
ability) or efflux pumps in combination with ESBL and/or
AmpC enzymes were most likely the major mechanisms
conferring carbapenem resistance among Enter-
obacteriaceae in Taiwan, as seen in other countries.26e28 In
this SMART study conducted in 2007, when KPC (especially
KPC-2) did not prevail in ICU settings in Taiwan, we clearly
demonstrated that only a low (<5.0%) percentage of
important enteric GNB species, with the exception of P.
mirabilis, displayed nonsusceptibility to imipenem. In
contrast to the data reported in the SMART 2005 study,29 we
found that the ESBL and non-ESBL subgroups of P. mirabilisisolates obtained from ICUs were also significantly more
nonsusceptible to imipenem than to meropenem and erta-
penem (50%/32.8% vs. 0%/1.6% and 0%/0%) based on CLSI
2014 criteria, a finding consistent with that in a recent
survey on GNB species responsible for intra-abdominal in-
fections in China.30 Mehtar et al31 reported that clinical P.
mirabilis isolates with imipenem MICs > 4 mg/mL predicted
treatment failure of imipenem. In this survey, only two (2/
14, 14.3%) ESBL-producing P. mirabilis isolates and none (0/
64, 0%) of the non-ESBL-producing P. mirabilis isolates had
imipenem MICs > 4 mg/mL. Therefore, the effect of a MIC
limit of 4 mg/mL on P. mirabilis analyzed in our ICU study
was trivial. In addition, a recent study by Tsai et al,32 who
investigated 47 patients with bacteremia caused by ESBL-
producing P. mirabilis isolates, reported that none of the
three patients with infections due to ESBL-producing P.
mirabilis isolates exhibiting imipenem MIC values 2 mg/mL
who were treated with imipenem died within 28 days of
diagnosis. Further investigations are needed to determine
whether the imipenem MIC breakpoint for P. mirabilis iso-
lates should be adjusted. In our study, only three (14.2%) of
21 imipenem-nonsusceptible P. mirabilis isolates were
nonsusceptible to cefotaxime and ceftazidime (data not
shown). The reason for that finding is probably because
most of these imipenem-nonsusceptible P. mirabilis iso-
lates lack imipenem-specific outer membrane proteins,31
have diminished PBP1a expression, or reduced imipenem
binding to PBP2.33
There are a few limitations in this study. First, the ex-
istence of clonal dissemination could not be completely
excluded. Second, we did not characterize the molecular
type of SCCmec among MRSA isolates.
In summary, based on 2014 MIC breakpoints recom-
mended by the CLSI, colistin showed only moderate in vitro
activity against P. aeruginosa and E. cloacae isolates ob-
tained from ICUs in Taiwan in 2007. Ceftobiprole showed
excellent bactericidal activity against MRSA isolates
regardless of their oxacillin MIC levels. These two agents
exhibited acceptable in vitro activities against P. aerugi-
nosa isolates. The clinical importance of high imipenem
nonsusceptibility among P. mirabilis isolates based on CLSI
2014 criteria remains debatable. Uninterrupted monitoring
of susceptibility profiles of some important ICU pathogens
to important antibiotics is still warranted.Conflicts of interest
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